Eagle Pharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Eagle Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 28.4% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
Sep 21Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Jul 13Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly
Jun 21These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Oct 27Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia
Oct 12Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose
Sep 27Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court
Aug 18Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be
Aug 15Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M
Aug 09These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Jul 06Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price
Apr 29In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eagle Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2023 | 258 | 12 | -9 | -9 | N/A |
3/31/2023 | 267 | -3 | 34 | 34 | N/A |
12/31/2022 | 317 | 36 | 51 | 51 | N/A |
9/30/2022 | 298 | 21 | 21 | 21 | N/A |
6/30/2022 | 272 | 23 | 35 | 36 | N/A |
3/31/2022 | 246 | 36 | 1 | 1 | N/A |
12/31/2021 | 172 | -9 | 28 | 28 | N/A |
9/30/2021 | 179 | 6 | 39 | 40 | N/A |
6/30/2021 | 189 | 18 | 44 | 44 | N/A |
3/31/2021 | 183 | 14 | 56 | 57 | N/A |
12/31/2020 | 188 | 12 | 49 | 49 | N/A |
9/30/2020 | 186 | 5 | 26 | 27 | N/A |
6/30/2020 | 177 | -5 | 31 | 32 | N/A |
3/31/2020 | 192 | 2 | 32 | 33 | N/A |
12/31/2019 | 196 | 14 | 55 | 56 | N/A |
9/30/2019 | 204 | 26 | 97 | 97 | N/A |
6/30/2019 | 214 | 42 | 90 | 90 | N/A |
3/31/2019 | 216 | 38 | 73 | 74 | N/A |
12/31/2018 | 213 | 32 | 52 | 52 | N/A |
9/30/2018 | 204 | 28 | 37 | 40 | N/A |
6/30/2018 | 216 | 30 | 40 | 44 | N/A |
3/31/2018 | 207 | 32 | 72 | 76 | N/A |
12/31/2017 | 237 | 52 | 54 | 59 | N/A |
9/30/2017 | 271 | 100 | 69 | 73 | N/A |
6/30/2017 | 246 | 97 | 62 | 78 | N/A |
3/31/2017 | 237 | 105 | N/A | 38 | N/A |
12/31/2016 | 189 | 81 | N/A | 53 | N/A |
9/30/2016 | 127 | 25 | N/A | -3 | N/A |
6/30/2016 | 94 | 3 | N/A | -23 | N/A |
3/31/2016 | 60 | -18 | N/A | -32 | N/A |
12/31/2015 | 66 | 3 | N/A | -10 | N/A |
9/30/2015 | 54 | -4 | N/A | -1 | N/A |
6/30/2015 | 51 | -3 | N/A | -1 | N/A |
3/31/2015 | 51 | 2 | N/A | 7 | N/A |
12/31/2014 | 20 | -21 | N/A | -22 | N/A |
9/30/2014 | 19 | -20 | N/A | -14 | N/A |
6/30/2014 | 17 | -11 | N/A | -7 | N/A |
3/31/2014 | 20 | -9 | N/A | -5 | N/A |
12/31/2013 | 18 | -11 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if EGRX's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if EGRX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if EGRX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if EGRX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if EGRX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EGRX's Return on Equity is forecast to be high in 3 years time